KPV vs Melanotan II
Both KPV and Melanotan II are used for skin. Here's how their evidence, dosing, and regulatory status actually compare.
KPV
Evidence C+α-MSH Tripeptide KPV
The C-terminal tripeptide of α-MSH with documented anti-inflammatory activity in IBD and dermatitis preclinical models. Frequently delivered orally and topically.
View full KPV profile →Melanotan II
Evidence C+Melanotan II (MT-II)
A non-selective melanocortin agonist (MC1R/MC3R/MC4R) that produces tanning and erection effects. Significant safety concerns including melanoma case reports.
View full Melanotan II profile →Side-by-Side
| Attribute | KPV | Melanotan II |
|---|---|---|
| Evidence Grade | C+ | C+ |
| FDA Status | Not FDA-approved — research peptide | Not FDA-approved — sold illegally as cosmetic; FDA warning letters issued |
| Typical Dose | 200–500 mcg orally or topical (research only) | 0.25–1 mg daily during loading, then maintenance (subcutaneous) |
| Clinics Indexed | 26 | 18 |
| Categories | anti-inflammatory, gut-health, skin | skin, sexual-health |
Key reported benefits — KPV
- ✓GI inflammation reduction
- ✓Skin inflammation reduction
- ✓Antimicrobial activity
Key reported benefits — Melanotan II
- ✓UV-independent tanning
- ✓Erectile effect (off-label)
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.